| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 11043 |
|
2,462 |
1,084 |
$152K |
| G6015 |
Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session |
1,031 |
112 |
$43K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,469 |
916 |
$27K |
| 77014 |
|
679 |
78 |
$14K |
| 11046 |
|
1,620 |
185 |
$13K |
| 77427 |
|
593 |
221 |
$12K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
216 |
169 |
$12K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
479 |
238 |
$10K |
| 77336 |
|
405 |
142 |
$8K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
980 |
628 |
$8K |
| 11044 |
|
56 |
25 |
$5K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
447 |
262 |
$1K |
| 77300 |
|
25 |
15 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
84 |
65 |
$956.62 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
52 |
51 |
$725.00 |
| 77263 |
|
20 |
13 |
$658.24 |
| 99223 |
Prolong inpt eval add15 m |
16 |
16 |
$565.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
40 |
39 |
$444.80 |
| 51798 |
|
90 |
66 |
$194.92 |
| 36415 |
Collection of venous blood by venipuncture |
217 |
131 |
$90.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
36 |
12 |
$63.21 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
33 |
17 |
$18.23 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
229 |
161 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
234 |
163 |
$0.00 |
| 4040F |
|
13 |
12 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
162 |
106 |
$0.00 |
| G8433 |
Screening for depression not completed, documented patient or medical reason |
44 |
41 |
$0.00 |
| 1036F |
|
140 |
100 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
140 |
100 |
$0.00 |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
16 |
13 |
$0.00 |